Search results
13 paź 2022 · Welcome to the British Journal of Cancer. The BJC is devoted to publishing cutting edge discovery, translational and clinical cancer research across the broad spectrum of oncology. Featured....
- Research articles
Read the latest Research articles from British Journal of...
- Reviews & Analysis
Read the Reviews & Analysis articles from British Journal of...
- News & Comment
Read the latest News & Comment articles from British Journal...
- Current issue
British Journal of Cancer (Br J Cancer) ISSN 1532-1827...
- Collections
Emerging Leaders - British Journal of Cancer BJC ’s Emerging...
- Journal Information
The British Journal of Cancer (BJC) is one of the most cited...
- Open access publishing
British Journal of Cancer are published OA under a CC BY...
- About the Editors
Jeff Evans is a Group Leader (Translational Cancer...
- Research articles
3 dni temu · Identification of a 5-gene signature panel for the prediction of prostate cancer progression. Michelle Shen. Fernando García-Marqués. Tanya Stoyanova. Article Open Access 14 Oct 2024.
14 wrz 2020 · Guide to Authors | British Journal of Cancer. On this page: Article types | Preparing your manuscript | Licence type | Open Access | Colour charges | Author tutorials | Journal cover...
An analysis of other primary cancers in individuals with non-Hodgkin's lymphoma (NHL) can help to elucidate this cancer aetiology. In all, 109 451 first primary NHL were included in a pooled ...
The British Journal of Cancer (BJC) is a twice-monthly professional medical journal published by Springer Nature.. The BJC provides a forum for clinicians and scientists to communicate original research findings that have relevance to understanding the etiology of cancer and to improving patient treatment and survival. Once accepted, papers are published in print and online.
Introduction. Non–muscle invasive bladder cancer (NMIBC) represents ap-proximately 75% of all newly diagnosed cases of bladder can-cer, and high-risk NMIBC accounts for approximately one third of the disease burden [1].
Purpose: Chemotherapy regimens with a 5-fluorouracil– (5-FU–) based backbone, such as mFOLFOX6, are preferred first-line treatments for patients with metastatic colorectal cancer (mCRC). Providers may empirically eliminate the 5-FU bolus because of hematologic toxicities.
